open access

Vol 27, No 4 (2020)
Editorial comment — Clinical cardiology
Published online: 2020-05-14
Get Citation

Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm

Justyna Domienik-Karłowicz, Miłosz Jaguszewski, Marcin Kurzyna
DOI: 10.5603/CJ.a2020.0067
·
Pubmed: 32419129
·
Cardiol J 2020;27(4):347-349.

open access

Vol 27, No 4 (2020)
Editorial comment — Clinical cardiology
Published online: 2020-05-14

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm

Journal

Cardiology Journal

Issue

Vol 27, No 4 (2020)

Pages

347-349

Published online

2020-05-14

DOI

10.5603/CJ.a2020.0067

Pubmed

32419129

Bibliographic record

Cardiol J 2020;27(4):347-349.

Authors

Justyna Domienik-Karłowicz
Miłosz Jaguszewski
Marcin Kurzyna

References (8)
  1. Agnelli G, Becattini C, Meyer G, et al. Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382(17): 1599–1607.
  2. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27(29): 4902–4911.
  3. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
  4. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012; 9(7): e1001275.
  5. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–153.
  6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41(4): 543–603.
  7. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
  8. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl